Real World Practice With Academic Anti CD19 CAR-T Cell Therapy in Relapse/Refractory B-cell Lymphoma

Chimeric antigen receptor (CAR) T-cell therapy has been the standard of care for relapsed/refractory large B-cell lymphomas (R/R LBCLs) since 2018. However, high cost of commercial products limits the...

Lead sponsor: N.N. Alexandrov National Cancer Centre•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Natalya Konoplya, PhD, MD, Professor

CONTACT

+375297723101 NKonoplya@mail.ru

Related studies

Active Not RecruitingPhase 3

Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma

NCT05605899 · High-risk Large B-cell Lymphoma (LBCL)

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 13, 2026Terms

Trial snapshot

StatusRECRUITING

Phase—

Enrollment76

Start dateJun 2021

Last updatedApr 13, 2026

Condition

Large B-Cell Lymphoma (LBCL)

Locations shown

NN Alexandrov National Cancer Centre of Belarus

Lyasny, Minsk Oblast

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 13, 2026Data synced to Clareo: May 17, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions